Deletion Mutants of BMP Folding Variants Act as BMP Antagonists and Are Efficient Inhibitors for Heterotopic Ossification

Journal of Bone and Mineral Research

Volumn 18, Issue 12, 2003, Pages 2142-2151

  Weber, Franz E ^a,b   Schmökel, Hugo ^c   Oelgeschläger, Michael ^d   Nickel, Joachim ^e   Maly, Friedrich E ^a   Hortschansky, Peter ^f   Grätz, Klaus W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f H K Inst fur Naturstoff Forschung   (Germany)

Author keywords

Bone morphogenetic protein; Bone morphogenetic protein antagonist; Bone morphogenetic protein folding variant; Bone morphogenetic protein receptor; Heterotopic ossification

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN INHIBITOR; BONE MORPHOGENETIC PROTEIN RECEPTOR; CALCIUM ION; NOGGIN; PROTEIN SUBUNIT; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSENSOR; BONE DEVELOPMENT; BONE MINERALIZATION; CALCIFICATION; CONTROLLED STUDY; DELETION MUTANT; EMBRYO; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HETEROTOPIC OSSIFICATION; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; RAT; RODENT; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; XENOPUS LAEVIS;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; BASE SEQUENCE; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; CARRIER PROTEINS; DNA PRIMERS; EMBRYO, NONMAMMALIAN; HUMANS; MICE; MODELS, ANIMAL; MUTAGENESIS; OSTEOBLASTS; OSTEOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN FOLDING; PROTEINS; RECOMBINANT PROTEINS; SEQUENCE DELETION; VARIATION (GENETICS); XENOPUS LAEVIS;

EID: 0344011546     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.12.2142     Document Type: Article

References (44)

1. Eulert J, Knelles D, Barthel T 1997 Heterotope Ossifikation. Unfallchirurg 100:667-674.
2. Nilsson OS 1998 Heterotopic ossification. Acta Orthop Scand 69:103-106.
3. Seegenschmiedt MH, Keilholz L, Martus P, Goldmann A, Wölfel R, Henning F, Sauer R 1997 Prevention of heterotopic ossification about the hip: Final results of two randomized trials in 410 patients using either preoperative or postoperative radiotherapy. Int J Radiat Oncol Biol Phys 39:161-171.
4. Dahl HK 1975 Klinske Observasjoner. In: Blindern MSD (ed.) Symposium on Arthrose. Language Service Inc., Hastings-on-Hudson, NY, USA, pp. 37-46.
5. Coventry MB, Scanlon PW 1981 The use of radiation to discourage ectopic bone: A nine-year study in surgery about the hip. J Bone Joint Surg Am 63:201-208.
6. Wozney JM, Rosen V 1998 Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 346:26-37.
7. Daopin S, Piez K, Ogawa Y, Davies DR 1992 Crystal structure of transforming growth factor-beta2: An unusual fold for the super-family. Science 257:369-373.
8. Scheufeler C, Sebald W, Hülsmeyer M 1999 Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol 287:103-115.
9. Massagué J 1998 TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
10. Kawabata M, Imamura T, Miyazono K 1998 Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9:49-61.
11. Hogan BLM 1996 Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
12. DeRobertis E, Larrain J, Oelschlaeger M, Wessely O 2002 The establishment of Spemann's organizer and patterning of the vertebrate embryo. Nat Rev Genet 1:171-181.
13. Smith JC 1995 Mesoderm-inducing factors and mesodermal patterning. Curr Opin Cell Biol 7:856-861.
14. Zimmerman LB, Dejesusescobar JM, Harland RM 1996 The Spemann organizer signal Noggin binds and inactivates bone morphogenetic protein 4. Cell 86:599-606.
15. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Belmonte JC, Choe S 2002 Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420:636-642.
16. Weber FE, Eyrich G, Grätz KW, Thomas RM, Maly FE, Sailer HF 2001 Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochem Biophys Res Commun 286:554-558.
17. Braman J, Papworth C, Greener A 1996 Site-directed mutagenesis using double stranded plasmid DNA templates. Methods Mol Biol 57:31-44.
18. Studier FW, Rosenberg AH, Dunn JJ, Dubendorf JW 1990 Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 185:60-89.
19. Lowry OH, Roberts NR, Wu M-L, Hixon WS, Crawford EJ 1954 The quantitative histochemistry of brain: II enzyme measurements. J Biol Chem 207:19-37.
20. Stanford CM, Jacobson PA, Eanes ED, Lembke LA, Midura RJ 1995 Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol Chem 270:9420-9428.
21. Muthukumaran N, Ma S, Reddi AH 1988 Dose-dependence of the threshold for optimal bone induction by collagenous bone matrix and osteogenin-enriched fraction. Collagen Rel Res 8:433-441.
22. Hammonds RG, Schwall R, Dudley A, Berkemeier L, Lai C, Lee J, Cunningham N, Reddi AH, Wood W, Mason AJ 1990 Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. Mol Endocrinol 4:149-155.
23. Sheehan DC, Hrapchak BB 1980 Bone. In: Sheehan DC, Hrapchak-BB (eds.) Theory and Practice of Histotechnology, 2nd ed. The CV Mosby Company, St Louis, MO, USA, pp. 89-117.
24. Nieuwkoop PD, Faber J 1994 Defined external and internal stage criteria. In: Niewkoop PD, Faber J (eds.) Normal Table of Xenopus Laevis. Garland Publishing, New York, NY, USA, pp. 60-94.
25. Lorrain J, Oelgeschläger M, Ketpura NI, Reversade B, Zakin L, DeRobertis EM 2001 Proteolytic cleavage of chordin as a switch for the dual activities of twisted gastrulation in BMP signaling. Development 128:4439-4447.
26. Kirsch T, Nickel J, Sebald W 2000 BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 19:3314-3324.
27. Natsume T, Tomita S, Iemura S, Kinto N, Yamaguchi A, Ueno N 1997 Interaction between soluble type I receptor for bone morphogenetic protein and bone morphogenetic protein-4. J Biol Chem 272:11535-11540.
28. DiCesare PE, Nimni ME, Peng L, Yazdi M, Cheung DT 1991 Effects of indomethacin on demineralized bone-induced heterotopic ossification in the rat. J Orthop Res 9:855-861.
29. O'Connor JP 1998 Animal models of heterotopic ossification. Clin Orthop 346:71-80.
30. Wilson PA, Lagna G, Suzuki A, Hemmati-Brivanlou A 1997 Concentration dependent patterning of the Xenopus ectoderm by BMP4 and its signal transducer Smad1. Development 124:3177-3184.
31. Wessely O, Agius E, Oelgeschläger M, Pera EM, DeRobertis EM 2001 Neural induction in the absence of mesoderm: Beta-catenin-dependent expression of secreted BMP antagonists at the blastula stage in Xenopus. Dev Biol 234:161-173.
32. Muller YA, Christinger HW, Keyt BA, de Vos AM 1997 The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93A resolution: Multiple copy flexibility and receptor binding. Structure (Camb) 5:1325-1338.
33. Gerber H-P, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N 1999 VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628.
34. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K 2002 Activation of ERK1/2 and JNK by transforming growth factor beta negatively regulates Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 277:36024-36031.
35. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT 2002 Bone morphogenetic proteins, extracellular matrix, and mitogen activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 17:101-110.
36. Aspenberg P, Jeppson C, Economides AN 2001 The bone morphogenetic protein antagonist noggin inhibits membranous ossification. J Bone Miner Res 16:497-500.
37. Ohkawara B, Iemura S-I, TenDijke P, Ueno N 2002 Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 12:205-209.
38. Teleman AA, Strigini M, Cohen SM 2001 Shaping morphogen gradients. Cell 105:559-561.
39. Christian JL 2000 BMP, Wnt, and hedgehog signals: How far can they go? Curr Opin Cell Biol 12:244-249.
40. Weber FE, Eyrich G, Grätz KW, Maly FE, Sailer HF 2002 Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly (lactide-co-glycolide) foam-spheres. Int J Oral Maxillofac Surg 31:60-65.
41. Lutolf MP, Weber FE, Schmökel HG, Schense JC, Kohler T, Müller R, Hubbell JA 2003 Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 21:513-518.
42. Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang J-X, Panganiban-Lustan L, Statton JR, Apell G, Winter JA, Doyle MV, Rosenberg S, Kavanaugh WM 1999 Semi-rational design of a potent, artificial agonist of fibroblast growth factor receptor. Nat Biotechnol 17:1199-1204.
43. Sijjad AQ, Kim RM, Konteatis Z, Biazzo DE, Motamed H, Rodrigues R, Boice J, Calaycay R, Bednarek MA, Griffin P, Goa Y-D, Chapman K, Mark DF 1999 Mimicry of erythropoietin by nonpeptide molecules. Proc Natl Acad Sci USA 96:12156-12161.
44. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Traub R, Murnke M, Kaplan FS 1996 Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561.